国医大师熊继柏运用补阳还五汤合得效方治疗硬皮病经验  被引量:5

Experience of National Traditional Chinese Medicine Master XIONG Jibo in Treating Systemic Sclerosis with Buyang Huanwu Decoction and Dexiao Decoction

在线阅读下载全文

作  者:文维农 姚欣艳[2,3] 刘侃 谭超[2,3] 刘朝圣 张维维[4] WEN Weinong;YAO Xinyan;LIU Kan;TAN Chao;LIU Chaosheng;ZHANG Weiwei(Hunan University of Chinese Medicine,Hunan Changsha 410208,China;The First Hospital of Hunan University of Chinese Medicine,Hunan Changsha 410007,China;Inherit Workroom of Medical Master Professor XIONG Jibo’s Experiences,Hunan Changsha 410007,China;Shenzhen Bao’an Hosptial of Traditional Chinese Medicine,Guangdong Shenzhen 518100,China)

机构地区:[1]湖南中医药大学,湖南长沙410208 [2]湖南中医药大学第一附属医院,湖南长沙410007 [3]国医大师熊继柏传承工作室,湖南长沙410007 [4]深圳市宝安区中医院(集团),广东深圳518100

出  处:《中医药临床杂志》2021年第6期1040-1043,共4页Clinical Journal of Traditional Chinese Medicine

基  金:国家中医药管理局“国医大师熊继柏传承工作室建设项目”资助。

摘  要:硬皮病是一种以皮肤变硬和增厚为主要表现的临床难治性疾病,多发于30~50岁女性。目前西医治疗主要以抗炎和免疫调节为主,以及针对相关血管病变、抗纤维化和手术移植等治疗,但其副作用大。祖国医学在治疗该病有着独特疗效。熊老师认为硬皮病病机主要是经络阻隔,气血不通所致,气虚为本,络瘀为标。临床上通过采用补阳还五汤合得效方益气活血通络,治疗效果显著。Scleroderma is a clinically refractory disease characterized by hardening and thickening of the skin,which mostly occurs in women aged 30~50.At present,Western medicine treatment mainly focuses on anti-inflammatory and immune regulation,as well as treatments for related vascular diseases,anti-fibrosis,and surgical transplantation,but its side effects are large.Chinese medicine has a unique effect in treating this disease.XIONG believes that the pathogenesis of scleroderma is mainly caused by meridian barriers,Qi and blood impassability,qi deficiency as the basis,and collateral stasis as the target.Clinically,through the use of Buyang Huanwu decoction and Dexiao decoction to invigorate Qi,activate blood and dredge collaterals,the therapeutic effect is significant.

关 键 词:国医大师 熊继柏 硬皮病 气虚络瘀证 补阳还五汤 得效方 

分 类 号:R275.9[医药卫生—中西医结合]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象